Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2025 Dec 1.
Published in final edited form as: Environ Res. 2024 Sep 2;262(Pt 2):119910. doi: 10.1016/j.envres.2024.119910

Exposure to organophosphate ester flame retardants and plasticizers and associations with preeclampsia and blood pressure in pregnancy

Amir J Lueth 1, Paige A Bommarito 1, Danielle R Stevens 1, Barrett M Welch 2, David E Cantonwine 3, Maria Ospina 4, Antonia M Calafat 4, John D Meeker 5, Thomas F McElrath 3, Kelly K Ferguson 1
PMCID: PMC11568915  NIHMSID: NIHMS2023460  PMID: 39233027

Abstract

Background:

Organophosphate esters (OPEs), flame retardants and plasticizers found widely in consumer products, may impact vascularization processes in pregnancy. Yet, the association between maternal exposure to OPEs and both preeclampsia and blood pressure during pregnancy remains understudied.

Methods:

Within the LIFECODES Fetal Growth Study (N=900), we quantified 8 OPE metabolites from maternal urine collected at up to 3 time points during pregnancy and created within-subject geometric means. Outcomes included diagnosis of preeclampsia and longitudinal systolic (SBP) and diastolic (DBP) blood pressure measurements (mean=14 per participant). Cox proportional models were used to estimate associations between OPE metabolites and preeclampsia. Associations between average OPE metabolite concentrations and repeated blood pressure measurements were estimated using generalized estimating equations.

Results:

Five OPE metabolites were detected in at least 60% of samples; 3 metabolites detected less frequently (5-39%) were examined in an exploratory analysis as ever vs. never detectable in pregnancy. There were 46 cases of preeclampsia in our study population. Associations between OPE metabolites and preeclampsia were null. We noted several divergent associations between OPE metabolites and longitudinal blood pressure measurements. An interquartile range (IQR) difference in average bis(2-chloroethyl) phosphate concentrations was associated with a decrease in SBP (−0.81 mmHg, 95% confidence interval [CI]: −1.62, 0.00), and, conversely, bis(1-chloro-2-propyl) phosphate was associated with a slight increase in SBP (0.94 mmHg, 95% CI: 0.28, 1.61). We also noted a decrease in SBP in association with several metabolites with low detection frequency.

Conclusions:

We observed null associations between OPE metabolites and preeclampsia, but some positive and some inverse associations with blood pressure in pregnancy. While our study was well-designed to assess associations with blood pressure, future studies with a larger number of preeclampsia cases may be better poised to investigate the association between OPE metabolites and phenotypes of this heterogenous hypertensive disorder of pregnancy.

Keywords: Preeclampsia, blood pressure, hypertensive disorders of pregnancy, flame retardants, organophosphate, chemical exposure

INTRODUCTION:

Organophosphate esters (OPEs) are a class of synthetic chemicals with phosphoric acid-containing alkyl and or aryl groups in halogenated or non-halogenated forms that are used to delay ignition times and slow burn rates of materials (1–3). The use of OPEs was initiated to replace brominated flame retardants in consumer products (e.g., building materials, furniture, electronic devices, paint, floor polishes, and textiles) (4). Today, OPEs are also often used as plasticizers and lubricants and because OPEs are not chemically bonded to products they are a part of, such as food packaging, children’s toys, and personal care products (e.g., nail polish), they can migrate into indoor dust, resulting in inhalation exposure (3, 4). Production and usage of OPEs have increased sharply in the past years with a worldwide consumption exceeding 680,000 tons in 2015 and anticipated to exceed 860,000 tons by 2023 (5, 6). Several OPE metabolites are frequently detected in urine in the general U.S. population, including pregnant individuals, with at least 60% of the participants having detectable concentration (7–10).

Preeclampsia occurs when individuals develop elevated blood pressure and excess urinary protein after 20 weeks of gestation and complicates between 2% and 15% of all pregnancies globally and approximately 5.6% in the U.S. (11–16). Additionally, about 6-8% of pregnant individuals experience gestational hypertension and or an increase in blood pressure during pregnancy (13). Individuals who have had preeclampsia and or gestational hypertension blood pressure have a higher risk of developing heart disease later in life (17). Taken together, preeclampsia and elevated blood pressure in pregnancy are some of the leading causes of maternal, fetal, and newborn morbidity and mortality (11, 18). Growing evidence from epidemiologic and observational studies highlights that adverse pregnancy outcomes such as preeclampsia and gestational hypertension during pregnancy may be influenced by gestational exposure to chemical pollutants in the environment (19, 20).

Only one study to date has examined OPE flame retardants and plasticizers in association with these critical blood pressure-related pregnancy outcomes. In the Health Outcomes and Measures of the Environment (HOME) Study, investigators found that higher concentrations of urinary bis(2-chloroethyl) phosphate (BCEP) at 16- and 26-weeks’ gestation were associated with a modest increase of the highest recorded blood pressure at or after 20 weeks of pregnancy (21). No study to date has investigated the association between gestational exposure to OPEs and preeclampsia, a distinct disorder from elevated blood pressure in pregnancy. The evidence from the toxicological literature suggests that OPEs have the capacity to disrupt endocrine function, vascularization, and other mechanistic pathways that support the development of a healthy pregnancy (22). Thus, further investigation of the relationship between gestational OPE flame retardant and plasticizer exposure and preeclampsia and blood pressure in pregnancy is needed.

In this study, we aimed to assess the association between gestational urinary OPE metabolites and preeclampsia as well as longitudinal measurements of blood pressure in a large, prospective cohort of pregnant individuals. We hypothesized that an increase in urinary OPE metabolites would be associated with an elevated risk of developing preeclampsia as well as elevated blood pressure measurements.

METHODS:

Study population

This secondary analysis uses data from the LIFECODES Fetal Growth Study, a nested case-cohort study within the prospective LIFECODES pregnancy cohort (10). The LIFECODES pregnancy cohort has been enrolling participants at approximately 10 weeks of gestation at Brigham and Women’s Hospital in Boston, MA, since 2006 and is still ongoing. Participants are eligible if ≥18 years of age, planning to seek prenatal care and to deliver at Brigham and Women’s Hospital, and not carrying multiples greater than twins. The study protocol includes three study visits at approximately 10, 24, and 35 weeks of gestation where participants provide urine and EDTA plasma samples. Maternal pregnancy, health, and demographic characteristics were ascertained using questionnaires. All participants provided written informed consent and the study was approved by the Institutional Review Board at Brigham and Women’s Hospital and analysis of the data was deemed exempt by the National Institute of Environmental Health Sciences. In addition, analysis of de-identified samples at the Centers for Disease Control and Prevention (CDC) laboratory was determined not to constitute an engagement in human subject’s research.

The original purpose of the LIFECODES Fetal Growth study was to assess environmental influences on fetal growth outcomes. As such, participants were included in the study population if they had a singleton pregnancy that resulted in a live birth between 2008-2018 and had birthweight recorded in medical records. Selection into the Fetal Growth Study occurred in two phases. First, a random sub-cohort of 504 was selected from all eligible 3,330 participants. Second, two additional enrichment sets were sampled for small-for-gestational-age (SGA < 10th percentile birthweight-for-gestational age; n = 199) and large-for-gestational-age (LGA > 90th percentile birthweight-for-gestational age; n = 198) births (23). Of these 901 participants, exposure biomarkers were measured on 900 who were included in the final analytical sample. This current analysis was not designed to assess fetal growth outcomes, and as such we incorporated survey weights to account for sampling into the cohort according to guidelines for secondary analyses of case-cohort data (24–26).

Measurement of urinary OPE metabolites

Eight metabolites of OPEs were measured in urine samples collected at 3 study visits, at approximately 10, 26, and 35 weeks of gestation. The metabolites were: bis(2-chloroethyl) phosphate (BCEP), (bis(1-chloro-2-propyl) phosphate) (BCIPP), bis(1,3-dichloro-2-propyl) phosphate) (BDCIPP), di-n-butyl phosphate (DNBP), diphenyl phosphate (DPHP), 2,3,4,5-tetrabromobenzoic acid (tBBA), 2-((isopropyl)phenyl) phenyl hydrogen phosphate (iPPPP) and 4-((tert-butyl)phenyl) phenyl hydrogen phosphate (tBPPP). Analysis was performed at the CDC as described in detail previously (10, 27). Briefly, samples underwent enzymatic hydrolysis of the conjugated metabolites followed by concentration with solid phase extraction. OPE metabolites were then separated using high-performance liquid chromatography and quantified by isotope dilution tandem mass spectrometry. The limit of detection (LOD) for most metabolites was 0.10 ng/mL, except for tBBA, iPPPP, and tBPPP (0.05 ng/mL). OPE metabolite concentrations were naturally log-transformed to improve normality. Concentrations below the limit of detection were imputed with the LOD divided by the square root of 2.

To account for urine dilution, specific gravity was measured using a digital handheld refractometer (Atago Co., Ltd., Tokyo, Japan). We corrected concentrations of OPE biomarkers for urine dilution using the Boeniger method: ESG =Eo (SGMedian – 1) /( SGo – 1), where ESG was the SG-corrected exposure measurement, Eo was the observed exposure measurement, SGmedian was the population’s overall median SG (1.015), and SGo was the observed specific gravity (28, 29). Geometric means of log-transformed longitudinal metabolite concentrations were calculated to estimate average OPE exposure during pregnancy. Additionally, we operationalized biomarkers that were detected in fewer than 60% of the participants as dichotomized variables (ever vs. never detectable in pregnancy).

Preeclampsia and blood pressure

Diagnosis of preeclampsia was defined using the American College of Obstetricians and Gynecologists guidelines and verified by two Maternal Fetal Medicine certified physicians (11) with adjudication by a third if there was disagreement. At the same time, gestational age at onset of preeclampsia was also assessed. This clinical assessment is thus more robust to changes in diagnostic guidelines over the study period than diagnosis based on ICD code or combinations of variables (e.g., blood pressure, proteinuria). Systolic (SBP) and diastolic (DBP) blood pressure measurements were obtained via medical record abstraction. We removed outliers with blood pressure measurements outside of −/+ 4 standard deviation from population mean values for each gestational week. Additionally, we excluded blood pressure measurements taken 1 day prior to delivery or afterward, since blood pressure highly fluctuates leading up to and during labor.

Covariates

Study covariates were ascertained from self-completed questionnaires at the time of enrollment into the LIFECODES cohort, including maternal demographic characteristics, behavioral factors, and reproductive history (10). These included the participant’s age, pre-pregnancy body mass index (BMI, kg/m2), and self-reported race and ethnicity. Self-identified race and ethnicity was ascertained from questionnaire and was included as a proxy for relative social advantage and disadvantage, structural racism, and other unmeasured social determinants of health. The questionnaire allowed participants to self-identify with one or more of the following categories: Caucasian; Black; South Asian; East Asian; Native American or Pacific Islander; More than one race; Other; Unsure; and N/A. A write-in option was allowed as well. Hispanic ethnicity was asked in a separate question. Categories were condensed as follows to avoid small sample sizes within groups: Non-Hispanic White; Non-Hispanic Black; Hispanic; Asian; and Multiple Races or Other participants. Other covariates also included the highest level of educational attainment (high school or less, some college or technical school, college degree or greater), smoking and alcohol consumption during pregnancy, health insurance provider (private/HMO, self-pay/Medicaid/none), parity (0, 1, and 2+), the use of any assisted reproductive technology (ART) to conceive, fetal sex, and year of conception.

Statistical analysis

Distributions of baseline maternal demographic characteristics were reported for the overall analytical population and compared between individuals with and without preeclampsia. We examined the distributions of pregnancy-average OPE biomarker concentrations and detect vs. non-detect for low detection metabolites overall and by preeclampsia status. Measurements of SBP and DBP (mmHg) and gestational age at measurement were visualized using scatter plots. OPEs detected >60% were modeled as continuous variables (natural-log transformed pregnancy-averages) and OPEs detected <60% were modeled as dichotomous variables (i.e., ever vs. never detect in pregnancy). We did not adjust for co-exposures to other endocrine disrupting compounds (EDCs, e.g., phthalate metabolites) in our analysis, or consider joint effects, due to the novelty of this research question. Furthermore, the correlation between OPE biomarkers and other EDCs in our study population is low (data not shown) . This may be of interest for future work.

The associations between pregnancy-average urinary OPE metabolites and hazard ratio (HR) of preeclampsia were estimated using Cox proportional hazard models while accounting for the timing of preeclampsia diagnosis and censoring for gestational age at delivery. Cox models were adjusted for potential confounding variables identified a priori in the literature based on demonstrated associations with exposure (10) and outcome (31) and included maternal age, pre-pregnancy BMI, race and ethnicity, education, health insurance status, and parity. We tested non-linearity of associations between OPE exposure biomarkers and blood pressure by adding a quadratic term for OPE metabolite to our models. To estimate the association of OPE exposure and continuous blood pressure measurements, generalized estimating equations (GEE) models were used for each pregnancy-average OPE metabolite and longitudinal blood pressure measurements while adjusting for the same confounders included in the preeclampsia analysis. SBP and DBP were modeled separately.

We conducted several sensitivity analyses to test the robustness of our findings, as follows. First, we examined whether the association between pregnancy-average OPE metabolite and blood pressure changed based on when in pregnancy blood pressure was measured. Second, to ensure that exposure preceded the outcome, we reconstructed our analysis to assess the association of OPE metabolite concentrations at the 10-week visit with preeclampsia diagnosis and longitudinal measurements of SBP and DBP. Thirdly, because OPEs are suggested endocrine disrupting chemicals and may thus have different biologic effects based on sex of the fetus, we assessed effect modification by fetal sex for associations between OPE metabolites and blood pressure with stratified models (32). Fourth, because maternal smoking is a noted protective factor for preeclampsia and may have a substantial impact on the outcome (33), we additionally adjusted for maternal smoking status in models of OPE metabolites and blood pressure and removed smokers from the dataset for the preeclampsia analysis to examine the impact on results. Fifth, we created blood pressure models excluding participants with preeclampsia (n = 46), chronic hypertension (n = 43), and gestational hypertension (n = 33) reported in medical records in models of OPE metabolites and blood pressure, as they could be taking medications for hypertension that would mask effects of OPE metabolites. Sixth, we examined models of preeclampsia additionally adjusted for prior history of preeclampsia, which is a strong risk factor for disease (34) and similarly could obscure more subtle effects of OPE metabolites. Lastly, since etiology of preeclampsia phenotypes (i.e., early vs. late onset) may be distinct, we examined associations analysis to assess the relationship between OPE and preeclampsia phenotype (i.e., late onset preeclampsia).

We performed all analyses using inverse probability weights to account for sampling into the case cohort using the survey package in R (version 4.1.1 or higher) (35).

RESULTS:

Participant characteristics

Maternal demographic characteristics are presented in Table 1. Among the 900 study participants included in the present analysis, participants were mainly non-Hispanic White (53%) and well-educated (66% with a college degree or higher). Within this sample, 46 individuals had preeclampsia and 854 did not. Maternal demographic characteristics were similar between individuals with and without preeclampsia (Table 1). One noted exception was that 8% of participants with preeclampsia had a parity of 2 or more compared to 23% of those without preeclampsia.

Table 1.

Distribution of participant characteristics overall and by preeclampsia status (n, weighted %) in the LIFECODES Fetal Growth Study (N=900).

Characteristic Overall N = 900 Preeclampsia N = 46 No preeclampsia N = 854
Age
< 25 years 102 (11.5) 5 (10.3) 97 (11.5)
25.0 - 29.9 years 187 (20.3) 9 (16.8) 178 (20.4)
30.0 - 34.0 years 304 (34.3) 15 (37.1) 289 (34.2)
≥ 35.0 years 307 (34.0) 17 (35.8) 290 (33.9)
Pre-pregnancy BMI
< 25.0 kg/m2 461 (53.0) 16 (37.9) 445 (53.6)
25.0 - 29.9 kg/m2 212 (24.8) 14 (33.2) 198 (24.4)
> 30 kg/m2 216 (22.3) 16 (28.8) 200 (20.0)
Race and Ethnicity
Non-Hispanic White 517 (58.0) 20 (38.3) 497 (58.9)
Non-Hispanic Black 136 (13.9) 10 (20.7) 126 (13.6)
Hispanic 147 (16.4) 7 (18.1) 140 (16.4)
Asian 56 (6.0) 4 (9.5) 52 (5.9)
Multiple races/Other participants 44 (5.6) 5 (13.4) 39 (5.2)
Highest Education
High School or less 120 (12.7) 8 (19.0) 112 (12.4)
Some College or technical school 179 (21.0) 9 (16.8) 170 (21.2)
College Degree or greater 587 (66.4) 29 (64.2) 558 (66.5)
Health Insurance
Private/HMO 638 (72.8) 30 (65.1) 608 (73.2)
Self-Pay/Medicaid/None 252 (27.2) 16 (34.9) 236 (26.8)
Smoking during pregnancy
Yes 57 (7.1) 1 (3.9) 56 (7.3)
No 843 (92.2) 45 (96.1) 798 (92.7)
Alcohol consumption during pregnancy
Yes 55 (6.5) 1 (3.9) 54 (6.7)
No 837 (92.2) 45 (96.1) 792 (92.1)
Parity
0 344 (39.3) 22 (52.2) 322 (38.7)
1 353 (38.7 18 (39.7) 335 (38.7)
2+ 203 (21.9) 6 (8.2) 197 (22.6)
Use of ART to conceive
Yes 110 (12.5) 10 (23.7) 100 (12.0)
No 790 (87.5) 36 (76.3) 754 (88.0)
Fetal Sex
Male 478 (53.2) 24 (53.9) 454 (53.1)
Female 422 (46.8) 22 (46.1) 400 (46.9)
Year of conception
2007-2010 356 (40.6) 17 (35.7) 339 (40.8)
2011-2014 396 (45.8) 22 (46.1) 374 (45.7)
2015-2018 148 (13.7) 7 (18.1) 141 (13.5)

Note: number of missing observations (weighted %): pre-pregnancy BMI, n = 11 (1.2%); education, n =14 (2%); insurance provider, n = 10 (1%); alcohol consumption, n = 8 (1%).

Abbreviations: SD, standard deviation; BMI, body mass index; ART, assisted reproductive technologies; HMO, health maintenance organization.

All SBP and DBP measurements from participants in the study population are presented in Figure 1. The mean (range) number of SBP or DBP blood pressure measurements per person was 13.8 (4–30).

Figure 1.

Figure 1.

Systolic and diastolic blood pressure measurements (mmHg) by gestational age at measurement among participants from the LIFECODES Fetal Growth Study (N=900).

Abbreviations: mmHg, millimeters of mercury

OPE metabolites

Five OPE metabolites, namely, BCEP, BCIPP, BDCIPP, DNBP, and DPHP were detected in at least 60% of samples analyzed (Supplemental Table 1). In our prior study, OPE biomarkers were highly variable over pregnancy. The ICC for each of the OPE metabolites suggested low-to moderate reliability over pregnancy (ICC range: 0.27-0.51) (10). By contrast, iPPPP, tBBA, and tBPPP had the lowest detection frequencies (5%-39%), although their LOD was 0.05 ng/mL compared to 0.1 ng/mL for the above five metabolites; these three OPE metabolites were analyzed subsequently as ever vs. never detectable in pregnancy. Concentrations and detection of metabolites were similar in individuals with preeclampsia vs. those without (Supplemental Table 2); however, iPPPP was detected in 21.3% of those with preeclampsia compared to 14.6% of those without preeclampsia. In general, OPE concentrations measured in LIFECODES participants were similar to or lower than the average concentration reported in the National Health and Nutrition Examination Survey for females’ participants of reproductive age, as reported in our previous work from this cohort (10).

Primary analyses

Associations between urinary OPE metabolites and preeclampsia were null in adjusted models (Table 2). HR for BCEP, BDCIPP, and iPPPP fell slightly above the null, but confidence intervals were wide. For example, an interquartile range (IQR) difference in pregnancy-average BCEP concentrations was associated with a hazard ratio of 1.10 (95% confidence interval [CI]=0.72, 1.68).

Table 2.

Adjusteda hazard ratios (95% confidence intervals) for preeclampsia in association with an interquartile range difference in ln-transformed pregnancy-average urinary OPE metabolite concentrations.

OPE metabolite Adjusted hazard ratio (95% confidence interval)
BCEP 1.10 (0.72, 1.68)
BCIPP 0.94 (0.63, 1.47)
BDCIPP 1.14 (0.67, 1.93)
DNBP 1.00 (0.69, 1.47)
DPHP 1.00 (0.63, 1.61)
iPPPPb 1.11 (0.46, 2.71)
tBBAb 0.82 (0.18, 3.80)
tBPPPb 0.84 (0.40, 1.76)
a

Hazard ratios were adjusted for maternal age, pre-pregnancy body mass index, race and ethnicity, education, health insurance status, and parity. n for preeclampsia=47

b

Indicates exposure biomarkers detected in fewer than 60% of the study participants and analyzed as detectable vs. non-detectable ever in pregnancy.

Abbreviations: OPE, organophosphate ester; BCEP, Bis(2-chloroethyl) phosphate; BCIPP, Bis(1-chloro-2-propyl) phosphate; BDCIPP, Bis(1,3-dichloro-2-propyl) phosphate; DNBP, Di-n-butyl phosphate; DPHP, Diphenyl phosphate; iPPPP, 2-((isopropyl)phenyl) phenyl hydrogen phosphate; tBBA, 2,3,4,5-tetrabromobenzoic acid; tBPPP, 4-((tert-butyl) phenyl) phenyl hydrogen phosphate.

We found no evidence of non-linear associations in the models with quadratic terms. Pregnancy-average OPE metabolite concentrations showed diverse associations with longitudinal blood pressure measurements (Figure 2, Supplemental Table 3). BCEP was associated with a slight decrease in SBP (−0.81 mmHg, 95% CI=−1.62, 0.00) and DBP (−0.38 mmHg, 95% CI=−1.01, 0.25). On the other hand, BCIPP was associated with a slight increase in SBP (0.94 mmHg, 95% CI: 0.28, 1.61) and DBP (0.46 mmHg, 95% CI=−0.11, 1.02). We also noted that the associations between the metabolites modeled as ever or never detectable in pregnancy, including iPPPP, tBBA, and tBPPP, and SBP and DBP were all inverse. For example, the detection of iPPPP ever in pregnancy was associated with a 2.31 mmHg decrease in SBP (95% CI: −3.89, −0.74) and a 1.73 mmHg decrease in DBP (95% CI: −3.00, −0.46).

Figure 2.

Figure 2.

Adjusteda difference in longitudinal systolic and diastolic blood pressure (mmHg) (95% confidence intervals) with an interquartile range difference in ln-transformed pregnancy-average urinary OPE metabolite concentrations.

aCalculated using a survey-weighted Generalized Estimating Equation model adjusting for maternal age, gestational age at blood measurement, pre-pregnancy BMI, race and ethnicity, education, health insurance status, smoking status, and parity.

*Exposure biomarkers (iPPPP, tBBA, tBPPP) detected in fewer than 60% of the study participants and analyzed as detectable vs. non-detectable ever in pregnancy.

Abbreviations: OPE, organophosphate ester; BCEP, Bis(2-chloroethyl) phosphate; BCIPP, Bis(1-chloro-2-propyl) phosphate; BDCIPP, Bis(1,3-dichloro-2-propyl) phosphate; DNBP, Di-n-butyl phosphate; DPHP, Diphenyl phosphate; iPPPP, 2-((isopropyl)phenyl) phenyl hydrogen phosphate; tBBA, 2,3,4,5-tetrabromobenzoic acid; tBPPP, 4-((tert-butyl) phenyl) phenyl hydrogen phosphate.

We additionally examined whether the association between pregnancy-average OPE metabolite and blood pressure changed based on when in pregnancy blood pressure was measured. In GEE models that included an interaction term between OPE metabolite and gestational age at blood pressure measurement, the interaction term was only significant (p=0.04) for BCIPP (Supplemental Table 4). The beta estimate for the interaction term was negative, indicating that the positive association between BCIPP and blood pressure observed in our primary analysis decreased in magnitude across pregnancy.

Sensitivity analyses

First, we examined associations between OPE metabolites measured at the 10-week visit, instead of the pregnancy-average, to ensure that the outcome occurred at or after the exposure assessment. As with our primary results, the associations between OPE metabolites measured at 10 weeks gestation and preeclampsia were not directionally consistent, and always included the null (Supplemental Table 5). For blood pressure analyses, most associations were attenuated toward the null (Supplemental Table 6). For example, the positive association observed in our primary analysis for BCEP was still inverse but closer to the null for SBP (−0.60 mmHg, 95% CI=−1.27,0.10) and DBP (−0.23 mmHg, 95% CI=−0.75, 0.28). BCIPP, however, was still positively associated with SBP (0.72 mmHg, 95% CI=0.09 1.34)

Second, we performed an analysis of associations between OPE metabolites and blood pressure measurements in models stratified by fetal sex. In general, associations were similar in direction and magnitude in pregnancies carrying a male or female fetus (Supplemental Table 7).

Third, results remained unchanged when we removed prior smokers from the analytical sample for assessing associations with preeclampsia (Supplemental Table 8) and when we additionally adjusted for maternal smoking status in models of pregnancy-average OPE metabolites and longitudinal SBP and DBP (Supplemental Table 9). Fourth, when we excluded individuals with preeclampsia, chronic hypertension, and gestational hypertension from models of blood pressure, associations remained consistent with primary analyses (Supplemental Table 10). Fifth, results for preeclampsia remained unchanged when we additionally adjusted for prior history of preeclampsia in the associations between OPE metabolites and preeclampsia (Supplemental Table 11). Lastly, associations between pregnancy-average OPE metabolites and late onset preeclampsia were very similar to what we observed for all preeclampsia (Supplemental Table 12).

DISCUSSION

Summary of findings

In this study, we investigated associations between maternal urinary OPE metabolites and preeclampsia and blood pressure during pregnancy in the LIFECODES Fetal Growth Study. We observed generally null associations between average OPE metabolite concentrations and preeclampsia. Additionally, in a study with a large number of longitudinal blood pressure measures, we observed diverse associations between OPE metabolites and SBP and DBP. Specifically, we observed positive associations between blood pressure and BCIPP, and inverse associations between blood pressure and BCEP as well as having detectable concentrations of iPPPP, tBBA, and tBPPP. The results for iPPPP, tBBA, and tBPPP with low detection must be interpreted with caution because detection frequency was low in our study population, despite a lower detection limit than other OPE metabolites (36). The results of this study add to the minimal existing literature on the effects of exposure to OPEs and blood pressure in pregnancy.

Comparison to prior studies

Only one prior study assessed the associations between gestational exposure to OPEs and hypertensive disorders of pregnancy and blood pressure. The HOME study (N=346) reported that an increase in pregnancy-average urinary BCEP concentrations was associated with a marginally significant increase of the highest recorded blood pressure at or after 20 weeks of pregnancy (B for a log10 increase=1.62 mmHg, 95% CI: 0.004, 3.24) (21). Additionally, they observed that urinary DNBP concentrations at 16 weeks gestation were associated with developing a hypertensive disorder of pregnancy, defined as: 1) having two SBP measurements ≥140 mmHg after 20 weeks gestation; 2) having two DBP measurements ≥90 mmHg after 20 weeks gestation; or 3) having any hypertensive disorder of pregnancy including (gestational hypertension, preeclampsia, eclampsia, HELLP syndrome) noted in the medical chart (21). They did not observe associations with other OPE metabolites measured.

Importantly, in our study we were able to isolate preeclampsia instead of combining it with other distinct hypertensive disorders in pregnancy; yet we still did not detect any associations. Regarding associations with blood pressure, our analytic approach was quite different. We examined associations between pregnancy-average OPE metabolite concentrations and longitudinal measures of blood pressure with the understanding that elevations in average blood pressure could be a part of adverse consequences for the pregnant person and/or developing fetus (37). Perhaps given these analytic differences, our results for BCEP were opposite what was observed in the HOME study; we observed inverse associations between pregnancy-average concentrations and gestational blood pressure measurements.

No other studies have examined iPPPP, tBBA, or tBPPP in association with preeclampsia or blood pressure in pregnancy. Contrary to our expectations, we observed inverse associations between the detection of iPPPP, tBBA, and tBPPP ever in pregnancy and longitudinal measures of blood pressure. However, given the limited range in concentrations of these exposure biomarkers in our study, these results must be interpreted with caution. This low detection likely reflects low exposure to corresponding parent compounds, which is similar to what is observed in the National Health and Nutrition Examination Survey (36). Furthermore, detection of these compounds decreased over time in our study population (10). Thus, replicating these findings in a population where exposures are higher may be impossible, and the importance of further studying these exposures may be waning.

Associations between OPE metabolites and blood pressure have been observed in cross-sectional studies of non-pregnant populations. One study observed that plasma triethyl phosphate concentrations, which we did not measure in our study, were associated with an increase in DBP in participants with hypertension (38). Another cross-sectional study of children and adolescents found weak positive correlations between urinary concentrations of BCEP, BCIPP, and DNBP and blood pressure, as well as a positive association between the OPE metabolite mixture and the risk of high blood pressure (39). Finally, in a study of adolescents, authors identified a positive association between urinary BDCIPP and SBP z-scores (40).

There is biological plausibility for an impact of OPE exposure on gestational blood pressure through mechanisms including endocrine disruption, oxidative stress, inflammation, vascular dysfunction, and placental dysfunction (23). OPEs can interfere with the hormonal signaling pathways that are involved in blood pressure regulation, especially through the renin-angiotensin-aldosterone system (RAAS) that helps to regulate blood pressure and fluid balance (24). Disruption of the RAAS pathway by OPEs may lead to dysregulation of blood pressure control and hypertensive disorders of pregnancy, including preeclampsia (24). OPEs have also been implicated in endothelial dysfunction, which is a key feature of preeclampsia (41). OPEs may directly impair endothelial function and vascular permeability, or indirectly influence revascularization that is necessary to support a healthy pregnancy (41). OPEs can also interact with vasoactive mediators, such as endothelin-1 (42). Through one or more of these pathways, OPEs may contribute to the preeclampsia hallmarks of hypertension and proteinuria (43). Furthermore, OPEs have been associated with an increase in reactive oxygen species production and elevated levels of pro-inflammatory cytokines and chemokines (44). Oxidative stress plays a role in the etiology of preeclampsia by contributing to endothelial dysfunction, placental ischemia, and maternal systemic inflammation (42, 44, 45). In preeclampsia cases, inflammation is exacerbated in response to placental ischemia (46). Finally, OPEs can disrupt placental perfusion and nutrient transport pathways by way of increasing reactive oxygen species production that exceeds antioxidant capacity (47), and through these or other pathways mentioned above, may lead to placental ischemia and hypoxia which are also implicated in the pathophysiology of preeclampsia (43, 47).

Limitations

Our study was not without limitations. Due to the low correlation between OPE biomarker concentration (r= −0.03 to 0.39) in our study population, as published in our previous work(30), we chose not to pursue questions pertaining to OPE mixtures in the present analysis (e.g., joint effects or co-exposure confounding).” While we had a large number of preeclampsia cases, we were still limited in our ability to assess associations with phenotypes of preeclampsia. We examined associations with late-onset preeclampsia which represented most of our cases (41 out of 46) but were unable to examine associations with early-onset. These phenotypes are different in terms of presentation as well as etiology. Late-onset preeclampsia is typically characterized by the absence of fetal growth restriction, whereas early-onset preeclampsia typically presents with fetal growth restriction (13, 48). Also, early and late onset preeclampsia cases arise from different mechanistic pathways involved in trophoblast development (49). Another limitation is that our study population was recruited from a high-risk tertiary care facility with a relatively high socioeconomic status. Thus, our findings may not be generalizable to the rest of the United States.

Strengths

Our study had several notable strengths. First, the diagnosis of preeclampsia in this study was adjudicated and validated by at least two Maternal-Fetal Medicine specialists. Second, we had a large number of longitudinal blood pressure measurements across gestation (mean=13.8 per participant), which provided a robust assessment of this outcome. OPE exposure biomarkers in this study were measured in urine specimens from up to three time points per participant in pregnancy, which was a significant improvement on studies assessing exposure from single spot urine specimens. OPEs are non-persistent chemicals with short half-lives within the body (e.g., on the order of days) (10). Consequently, as reported in our prior study and others’, single urinary OPE biomarkers have low to moderate reliability across pregnancy. Averaging concentrations of multiple measurements of OPE exposure across pregnancy is thus a better estimate of gestational OPE exposure than a single measure and substantially reduces exposure misclassification. (50).

CONCLUSION:

Our results contribute to the nascent body of literature assessing the association between OPE exposure during pregnancy, preeclampsia, and blood pressure. We observed null associations between OPE metabolites and diagnosis of preeclampsia. Associations with longitudinal blood pressure measurements were diverse. We noted positive associations between BCIPP and blood pressure, and inverse associations for BCEP. We also observed inverse associations between having detectable concentrations of several metabolites (iPPPP, tBBA, and tBPPP) and longitudinal blood pressure measurements; however, these results must be interpreted with caution because detection frequency was so low in our study population, even though these compounds had a detection limit that was lower than other compounds measured in our study. Future research studies in this area should be designed specifically to address the potential effects of OPE exposure on preeclampsia and longitudinal blood pressure measurements.

Supplementary Material

1

Highlights:

  • Eight OPE metabolites were measured from maternal urine at up to 3 time points during pregnancy

  • Longitudinal systolic (SBP), and diastolic (DBP) blood pressure measurements (mean=14 per participant)

  • No significant associations between OPE metabolites and preeclampsia

  • Positive associations between BCIPP and blood pressure, and inverse associations for BCEP

  • Decrease in SBP noted with several metabolites with low detection frequency

Funding acknowledgements

This research was funded by the Intramural Research Program of the National Institute of Environmental Health Sciences, National Institutes of Health (ZIAES103321). The funder had no role in the conduct or reporting of this study.

Disclaimer:

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Use of trade names is for identification only and does not imply endorsement by the CDC, the Public Health Service, or the US Department of Health and Human Services.

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

REFERENCES:

  • 1.van der Veen I, de Boer J. Phosphorus flame retardants: properties, production, environmental occurrence, toxicity and analysis. Chemosphere. 2012;88(10):1119–53. Epub 2012/04/28. doi: 10.1016/j.chemosphere.2012.03.067. [DOI] [PubMed] [Google Scholar]
  • 2.Hoffman K, Lorenzo A, Butt CM, Adair L, Herring AH, Stapleton HM, Daniels JL. Predictors of urinary flame retardant concentration among pregnant women. Environ Int. 2017;98:96–101. Epub 2016/10/18. doi: 10.1016/j.envint.2016.10.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Millenson ME, Braun JM, Calafat AM, Barr DB, Huang YT, Chen A, Lanphear BP, Yolton K. Urinary organophosphate insecticide metabolite concentrations during pregnancy and children’s interpersonal, communication, repetitive, and stereotypic behaviors at 8 years of age: The home study. Environ Res. 2017;157:9–16. Epub 2017/05/16. doi: 10.1016/j.envres.2017.05.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Li J, Zhao L, Letcher RJ, Zhang Y, Jian K, Zhang J, Su G. A review on organophosphate Ester (OPE) flame retardants and plasticizers in foodstuffs: Levels, distribution, human dietary exposure, and future directions. Environ Int. 2019;127:35–51. Epub 2019/03/23. doi: 10.1016/j.envint.2019.03.009. [DOI] [PubMed] [Google Scholar]
  • 5.Hou R, Xu Y, Wang Z. Review of OPFRs in animals and humans: Absorption, bioaccumulation, metabolism, and internal exposure research. Chemosphere. 2016;153:78–90. Epub 2016/03/25. doi: 10.1016/j.chemosphere.2016.03.003. [DOI] [PubMed] [Google Scholar]
  • 6.Bi R, Su G. Dietary intake assessment of known and unknown organophosphate esters (OPEs) in foodstuffs via high-resolution mass spectrometry. Sci Total Environ. 2023;854:158452. Epub 2022/09/06. doi: 10.1016/j.scitotenv.2022.158452. [DOI] [PubMed] [Google Scholar]
  • 7.Blum A, Behl M, Birnbaum L, Diamond ML, Phillips A, Singla V, Sipes NS, Stapleton HM, Venier M. Organophosphate Ester Flame Retardants: Are They a Regrettable Substitution for Polybrominated Diphenyl Ethers? Environ Sci Technol Lett. 2019;6(11):638–49. Epub 2020/06/05. doi: 10.1021/acs.estlett.9b00582. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Ospina M, Jayatilaka NK, Wong LY, Restrepo P, Calafat AM. Exposure to organophosphate flame retardant chemicals in the U.S. general population: Data from the 2013-2014 National Health and Nutrition Examination Survey. Environ Int. 2018;110:32–41. Epub 2017/11/06. doi: 10.1016/j.envint.2017.10.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Percy Z, La Guardia MJ, Xu Y, Hale RC, Dietrich KN, Lanphear BP, Yolton K, Vuong AM, Cecil KM, Braun JM, Xie C, Chen A. Concentrations and loadings of organophosphate and replacement brominated flame retardants in house dust from the home study during the PBDE phase-out. Chemosphere. 2020;239:124701. Epub 2019/09/10. doi: 10.1016/j.chemosphere.2019.124701. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Bommarito PA, Friedman A, Welch BM, Cantonwine DE, Ospina M, Calafat AM, Meeker JD, McElrath TF, Ferguson KK. Temporal trends and predictors of gestational exposure to organophosphate ester flame retardants and plasticizers. Environ Int. 2023;180:108194. Epub 2023/09/15. doi: 10.1016/j.envint.2023.108194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000;183(1):S1–s22. Epub 2000/08/02. [PubMed] [Google Scholar]
  • 12.Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122(5):1122–31. Epub 2013/10/24. doi: 10.1097/01.AOG.0000437382.03963.88. [DOI] [PubMed] [Google Scholar]
  • 13.American College of O, Gynecologists’ Committee on Practice B-O. ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy. Obstet Gynecol. 2019;133(1):e26–e50. Epub 2018/12/24. doi: 10.1097/AOG.0000000000003020. [DOI] [PubMed] [Google Scholar]
  • 14.Jeyabalan A. Epidemiology of preeclampsia: impact of obesity. Nutr Rev. 2013;71 Suppl 1(0 1):S18–25. Epub 2013/10/30. doi: 10.1111/nure.12055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Chang KJ, Seow KM, Chen KH. Preeclampsia: Recent Advances in Predicting, Preventing, and Managing the Maternal and Fetal Life-Threatening Condition. Int J Environ Res Public Health. 2023;20(4). Epub 2023/02/26. doi: 10.3390/ijerph20042994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Bibbins-Domingo K, Grossman DC, Curry SJ, Barry MJ, Davidson KW, Doubeni CA, Epling JW Jr., Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Phillips WR, Phipps MG, Silverstein M, Simon MA, Tseng CW. Screening for Preeclampsia: US Preventive Services Task Force Recommendation Statement. Jama. 2017;317(16):1661–7. Epub 2017/04/27. doi: 10.1001/jama.2017.3439. [DOI] [PubMed] [Google Scholar]
  • 17.Haas DM, Ehrenthal DB, Koch MA, Catov JM, Barnes SE, Facco F, Parker CB, Mercer BM, Bairey-Merz CN, Silver RM, Wapner RJ, Simhan HN, Hoffman MK, Grobman WA, Greenland P, Wing DA, Saade GR, Parry S, Zee PC, Reddy UM, Pemberton VL, Burwen DR, National Heart L, Blood Institute nuMo MbHHSN. Pregnancy as a Window to Future Cardiovascular Health: Design and Implementation of the nuMoM2b Heart Health Study. Am J Epidemiol. 2016;183(6):519–30. Epub 2016/01/31. doi: 10.1093/aje/kwv309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Whitehead SJ, Berg CJ, Chang J. Pregnancy-related mortality due to cardiomyopathy: United States, 1991-1997. Obstet Gynecol. 2003;102(6):1326–31. Epub 2003/12/10. doi: 10.1016/j.obstetgynecol.2003.08.009. [DOI] [PubMed] [Google Scholar]
  • 19.Ferguson KK, Chin HB. Environmental chemicals and preterm birth: Biological mechanisms and the state of the science. Curr Epidemiol Rep. 2017;4(1):56–71. Epub 2017/09/26. doi: 10.1007/s40471-017-0099-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Kamai EM, McElrath TF, Ferguson KK. Fetal growth in environmental epidemiology: mechanisms, limitations, and a review of associations with biomarkers of non-persistent chemical exposures during pregnancy. Environ Health. 2019;18(1):43. Epub 2019/05/10. doi: 10.1186/s12940-019-0480-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Yang W, Braun JM, Vuong AM, Percy Z, Xu Y, Xie C, Deka R, Calafat AM, Ospina M, Werner E, Yolton K, Cecil KM, Lanphear BP, Chen A. Maternal urinary OPE metabolite concentrations and blood pressure during pregnancy: The HOME study. Environ Res. 2022;207:112220. Epub 2021/10/18. doi: 10.1016/j.envres.2021.112220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Dishaw LV, Macaulay LJ, Roberts SC, Stapleton HM. Exposures, mechanisms, and impacts of endocrine-active flame retardants. Curr Opin Pharmacol. 2014;19:125–33. Epub 2014/10/13. doi: 10.1016/j.coph.2014.09.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Cantonwine DE, Ferguson KK, Mukherjee B, Chen YH, Smith NA, Robinson JN, Doubilet PM, Meeker JD, McElrath TF. Utilizing Longitudinal Measures of Fetal Growth to Create a Standard Method to Assess the Impacts of Maternal Disease and Environmental Exposure. PLoS One. 2016;11(1):e0146532. Epub 2016/01/06. doi: 10.1371/journal.pone.0146532. [DOI] [PMC free article] [PubMed] [Google Scholar]; funded in part by Abbott Diagnostics. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
  • 24.Cheung KL, Lafayette RA. Renal physiology of pregnancy. Adv Chronic Kidney Dis. 2013;20(3):209–14. Epub 2013/08/10. doi: 10.1053/j.ackd.2013.01.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.O’Brien KM, Lawrence KG, Keil AP. The Case for Case-Cohort: An Applied Epidemiologist’s Guide to Reframing Case-Cohort Studies to Improve Usability and Flexibility. Epidemiology. 2022;33(3):354–61. Epub 2022/04/07. doi: 10.1097/EDE.0000000000001469. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Richardson DB, Rzehak P, Klenk J, Weiland SK. Analyses of case-control data for additional outcomes. Epidemiology. 2007;18(4):441–5. Epub 2007/05/03. doi: 10.1097/EDE.0b013e318060d25c. [DOI] [PubMed] [Google Scholar]
  • 27.Jayatilaka NK, Restrepo P, Davis Z, Vidal M, Calafat AM, Ospina M. Quantification of 16 urinary biomarkers of exposure to flame retardants, plasticizers, and organophosphate insecticides for biomonitoring studies. Chemosphere. 2019;235:481–91. Epub 2019/07/05. doi: 10.1016/j.chemosphere.2019.06.181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Boeniger MF, Lowry LK, Rosenberg J. Interpretation of urine results used to assess chemical exposure with emphasis on creatinine adjustments: a review. Am Ind Hyg Assoc J. 1993;54(10):615–27. Epub 1993/10/01. doi: 10.1080/15298669391355134. [DOI] [PubMed] [Google Scholar]
  • 29.Kuiper JR, O’Brien KM, Ferguson KK, Buckley JP. Urinary specific gravity measures in the U.S. population: Implications for the adjustment of non-persistent chemical urinary biomarker data. Environ Int. 2021;156:106656. Epub 2021/06/02. doi: 10.1016/j.envint.2021.106656. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Bommarito PA, Stevens DR, Welch BM, Ospina M, Calafat AM, Meeker JD, Cantonwine DE, McElrath TF, Ferguson KK. Organophosphate Ester Flame Retardants and Plasticizers in Relation to Fetal Growth in the LIFECODES Fetal Growth Study. Environ Health Perspect. 2024;132(7):77001. Epub 2024/07/05. doi: 10.1289/ehp14647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Wheeler SM, Myers SO, Swamy GK, Myers ER. Estimated Prevalence of Risk Factors for Preeclampsia Among Individuals Giving Birth in the US in 2019. JAMA Netw Open. 2022;5(1):e2142343. Epub 2022/01/05. doi: 10.1001/jamanetworkopen.2021.42343. [DOI] [PMC free article] [PubMed] [Google Scholar]; Eunice Kennedy Shriver National Institute of Child Health and Human Development and National Institute of Allergy and Infectious Diseases, receiving personal fees from GlaxoSmithKline, Pfizer, and UpToDate Chair, and receiving grants from the Centers for Disease Control and Prevention outside the submitted work. No other disclosures were reported.
  • 32.Retnakaran R, Wen SW, Tan H, Zhou S, Ye C, Shen M, Smith GN, Walker MC. Maternal Blood Pressure Before Pregnancy and Sex of the Baby: A Prospective Preconception Cohort Study. Am J Hypertens. 2017;30(4):382–8. Epub 2017/01/07. doi: 10.1093/ajh/hpw165. [DOI] [PubMed] [Google Scholar]
  • 33.Rodriguez-Lopez M, Escobar MF, Merlo J, Kaufman JS. Reevaluating the protective effect of smoking on preeclampsia risk through the lens of bias. J Hum Hypertens. 2023;37(5):338–44. Epub 2023/04/12. doi: 10.1038/s41371-023-00827-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Boyd HA, Tahir H, Wohlfahrt J, Melbye M. Associations of personal and family preeclampsia history with the risk of early-, intermediate- and late-onset preeclampsia. Am J Epidemiol. 2013;178(11):1611–9. Epub 2013/09/21. doi: 10.1093/aje/kwt189. [DOI] [PubMed] [Google Scholar]
  • 35.Lumley T. Analysis of Complex Survey Samples. Journal of Statistical Software. 2004;9(8):1–19. doi: 10.18637/jss.v009.i08. [DOI] [Google Scholar]
  • 36.Boyle M, Buckley JP, Quirós-Alcalá L. Associations between urinary organophosphate ester metabolites and measures of adiposity among U.S. children and adults: NHANES 2013-2014. Environ Int. 2019;127:754–63. Epub 2019/04/20. doi: 10.1016/j.envint.2019.03.055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Hercus JC, Metcalfe KX, Christians JK. Sex differences in growth and mortality in pregnancy-associated hypertension. PLoS One. 2024;19(1):e0296853. Epub 2024/01/11. doi: 10.1371/journal.pone.0296853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Li Y, Li D, Chen J, Zhang S, Fu Y, Wang N, Liu Y, Zhang B. Presence of organophosphate esters in plasma of patients with hypertension in Hubei Province, China. Environ Sci Pollut Res Int. 2020;27(19):24059–69. Epub 2020/04/18. doi: 10.1007/s11356-020-08563-0. [DOI] [PubMed] [Google Scholar]
  • 39.Guo X, Ke Y, Wu B, Song Q, Sun C, Li Y, Wang H, Su W, Liang Q, Lowe S, Bentley R, Song EJ, King B, Zhou Q, Xie R, Deng F. Exploratory analysis of the association between organophosphate ester mixtures with high blood pressure of children and adolescents aged 8-17 years: cross-sectional findings from the National Health and Nutrition Examination Survey. Environ Sci Pollut Res Int. 2023;30(9):22900–12. Epub 2022/10/30. doi: 10.1007/s11356-022-23740-z. [DOI] [PubMed] [Google Scholar]
  • 40.Hu L, Yu M, Li Y, Liu L, Li X, Song L, Wang Y, Mei S. Association of exposure to organophosphate esters with increased blood pressure in children and adolescents. Environ Pollut. 2022;295:118685. Epub 2021/12/20. doi: 10.1016/j.envpol.2021.118685. [DOI] [PubMed] [Google Scholar]
  • 41.Possomato-Vieira JS, Khalil RA. Mechanisms of Endothelial Dysfunction in Hypertensive Pregnancy and Preeclampsia. Adv Pharmacol. 2016;77:361–431. Epub 2016/07/28. doi: 10.1016/bs.apha.2016.04.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Mallette JH, Crudup BF, Alexander BT. Growth Restriction in Preeclampsia: Lessons from Animal Models. Curr Opin Physiol. 2023;32. Epub 2023/03/28. doi: 10.1016/j.cophys.2023.100647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Le Y, Shen H, Yang Z, Lu D, Wang C. Comprehensive analysis of organophosphorus flame retardant-induced mitochondrial abnormalities: Potential role in lipid accumulation. Environ Pollut. 2021;274:116541. Epub 2021/02/03. doi: 10.1016/j.envpol.2021.116541. [DOI] [PubMed] [Google Scholar]
  • 44.Kupferminc MJ, Peaceman AM, Wigton TR, Rehnberg KA, Socol ML. Tumor necrosis factor-alpha is elevated in plasma and amniotic fluid of patients with severe preeclampsia. Am J Obstet Gynecol. 1994;170(6):1752–7; discussion 7-9. Epub 1994/06/01 [PubMed] [Google Scholar]
  • 45.Ingle ME, Watkins D, Rosario Z, VelezVega CM, Calafat AM, Ospina M, Ferguson KK, Cordero JF, Alshawabkeh A, Meeker JD. An exploratory analysis of urinary organophosphate ester metabolites and oxidative stress among pregnant women in Puerto Rico. Sci Total Environ. 2020;703:134798. Epub 2019/11/15. doi: 10.1016/j.scitotenv.2019.134798. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Sacks GP, Studena K, Sargent K, Redman CW. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am J Obstet Gynecol. 1998;179(1):80–6. Epub 1998/08/15. doi: 10.1016/s0002-9378(98)70254-6. [DOI] [PubMed] [Google Scholar]
  • 47.de Lucca L, Jantsch LB, Vendrame SA, de Paula HL, Dos Santos Stein C, Gallarreta FMP, Moresco RN, de Lima Goncalves T. Variation of the Oxidative Profile in Pregnant Women With and Without Gestational Complications. Matern Child Health J. 2022;26(10):2155–68. Epub 2022/08/16. doi: 10.1007/s10995-022-03475-6. [DOI] [PubMed] [Google Scholar]
  • 48.Liu T, Zhang M, Guallar E, Wang G, Hong X, Wang X, Mueller NT. Trace Minerals, Heavy Metals, and Preeclampsia: Findings from the Boston Birth Cohort. J Am Heart Assoc. 2019;8(16):e012436. Epub 2019/08/21. doi: 10.1161/JAHA.119.012436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Huppertz B. The Critical Role of Abnormal Trophoblast Development in the Etiology of Preeclampsia. Curr Pharm Biotechnol. 2018;19(10):771–80. Epub 2018/04/28. doi: 10.2174/1389201019666180427110547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Wang X, Liu Q, Zhong W, Yang L, Yang J, Covaci A, Zhu L. Estimating renal and hepatic clearance rates of organophosphate esters in humans: Impacts of intrinsic metabolism and binding affinity with plasma proteins. Environ Int. 2020;134:105321. Epub 2019/11/30. doi: 10.1016/j.envint.2019.105321. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1

RESOURCES